we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid 

Halozyme Therapeutics, Inc.

Bought 51% more HALO

This member connected a brokerage account and is sharing trades and portfolio performance with the community. 

Public Portfolio

Dustin Garner

Bought 101% more HALO

New position in HALO

Sold all HALO

ShanDoshi

Abilash Satya

Bought 60% more HALO

Bought 150% more HALO

Bought $1k-$15k HALO

This profile creates auto-generated trade alerts based on public disclosures.

Congressional Investor

Rep. Josh Gottheimer

Zachary Gardner

Sold 9% of HALO

Traded HALO

Mike Pelech

Sold 25% of HALO

Bought 33% more HALO

Bought 83% more HALO

Bought to close 140% HALO

Andrew Cameron

Matthieu Hafemeister